Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Castagna, L.
Right arrow Articles by Dietrich, P.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castagna, L.
Right arrow Articles by Dietrich, P.-Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:953-955, 2001
© 2001 European Society for Medical Oncology

research-article

Prevention of mucositis in bone marrow transplantation: A double blind randomised controlled trial of sucralfate

L. Castagna1,4, E. Benhamou2, E. Pedraza1, M. Luboinski2, M. Forni3, I. Brandes1, J.-L. Pico1 and P.-Y. Dietrich1,3,

1Department of Haematology BMT Unit
2Btostatistics Institut Gustave Roussy Villejuif France
3Division of Oncology, University Hospital Geneva, Switzerland
4Present address: Oncologv—Hematology Department, Istituto Clinico Hunianitas Rozzano (Ml) Italy

Pierre-Yves Dietrich, MD Hôpital Universitaire Division d'Oncologie 1211 Genéve 14 Switzerland E-mail:pierre-yves.dietrich{at}hcuge.ch

Mucositis is still a leading side effect of high dose chemotherapy and irradiation delivered in autologous and allogeneic bone marrow transplantation. In this double blind randomised study, we tested the efficacy of sucralfate for the prevention of mucositis induced by such conditioning treatments. Treatment was started one day before conditioning regimen and patients were prospectively evaluated. The main endpoint was severe mucositis that was more frequent in the placebo group than in the sucralfate group (47% vs. 29%, P = 0.07). This trend was confirmed after adjustment on total body irradiation (TBI) (P = 0.06), the sole stratification parameter. Interestingly, patients receiving sucralfate showed a significant reduction of diarrhoea (25% vs. 53%, P = 0.005). Overall, the preventive administration of sucralfate appears to be an effective proce dure to diminish the occurrence of severe oral and intestinal mucositis in patients treated by high dose chemotherapy alone or combined with TBI before bone marrow transplantation.

mucositis, stem-cell transplantation, sucralfate


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
P. J. Stiff, C. Emmanouilides, W. I. Bensinger, T. Gentile, B. Blazar, T. C. Shea, J. Lu, J. Isitt, A. Cesano, and R. Spielberger
Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting
J. Clin. Oncol., November 20, 2006; 24(33): 5186 - 5193.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
M.A. Stokman, F.K.L. Spijkervet, H.M. Boezen, J.P. Schouten, J.L.N. Roodenburg, and E.G.E. de Vries
Preventive Intervention Possibilities in Radiotherapy- and Chemotherapy-induced Oral Mucositis: Results of Meta-analyses
Journal of Dental Research, August 1, 2006; 85(8): 690 - 700.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.